Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study
Open Access
- 22 February 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (2) , e1003911
Abstract
Background: There is limited evidence on the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for selecting patients for advanced cardiovascular (CV) therapies in the modern era. The prognostic value of mildly elevated hsCRP beyond troponin in a large real-world cohort of unselected patients presenting with suspected acute coronary syndrome (ACS) is unknown. We evaluated whether a mildly elevated hsCRP (up to 15 mg/L) was associated with mortality risk, beyond troponin level, in patients with suspected ACS. Methods and findings: We conducted a retrospective cohort study based on the National Institute for Health Research Health Informatics Collaborative data of 257,948 patients with suspected ACS who had a troponin measured at 5 cardiac centres in the United Kingdom between 2010 and 2017. Patients were divided into 4 hsCRP groups (<2, 2 to 4.9, 5 to 9.9, and 10 to 15 mg/L). The main outcome measure was mortality within 3 years of index presentation. The association between hsCRP levels and all-cause mortality was assessed using multivariable Cox regression analysis adjusted for age, sex, haemoglobin, white cell count (WCC), platelet count, creatinine, and troponin. Following the exclusion criteria, there were 102,337 patients included in the analysis (hsCRP 15 mg/L makes it unlikely that sepsis was a major contributor. Conclusions: These multicentre, real-world data from a large cohort of patients with suspected ACS suggest that mildly elevated hsCRP (up to 15 mg/L) may be a clinically meaningful prognostic marker beyond troponin and point to its potential utility in selecting patients for novel treatments targeting inflammation. Trial registration: ClinicalTrials.gov - NCT03507309Keywords
Funding Information
- British Heart Foundation (FS/20/18/34972)
- Wellcome Trust (WIII_P67144)
- THIS Institute
- National Institute for Health Research (NF-SI-0611-10168)
- British Heart Foundation (CH/1999001/11735)
- British Heart Foundation (FS/14/76/30933)
- British Heart Foundation (RE/18/4/34215)
This publication has 32 references indexed in Scilit:
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease PredictionNew England Journal of Medicine, 2012
- Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health InitiativeCirculation, 2012
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysisThe Lancet, 2012
- Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant dataBMJ, 2011
- Prospective Study of High-Sensitivity C-Reactive Protein as a Determinant of Mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984–1998Clinical Chemistry, 2008
- C-reactive protein in patients with acute coronary syndrome: Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findingsInternational Journal of Cardiology, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A SubstudyJACC, 1998
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997
- Elevation of C-reactive protein in “active” coronary artery diseaseThe American Journal of Cardiology, 1990